EP300对口腔鳞癌细胞增殖和迁移的影响

doi:10.13591/j.cnki.kqyx.2024.02.002

摘要/Abstract

摘要：

目的探讨EP300在口腔鳞癌中的表达水平以及对口腔鳞癌细胞增殖、迁移的影响。方法通过在线数据库收集并分析EP300基因在泛癌组织及正常组织中的表达差异。采用qRT-PCR和Western blot分别检测EP300在正常口腔黏膜上皮细胞株NOK和两种不同OSCC细胞株HSC3、UM1中的基因和蛋白表达水平;通过质粒转染沉默HSC3和UM1细胞株中EP300基因,平板克隆和CCK-8检测细胞增殖能力,划痕实验检测细胞迁移能力。结果生信分析发现EP300在头颈部鳞癌HNSCC中的表达较癌旁组织显著上调;与NOK组比较,HSC3和UM1中EP300基因和蛋白表达水平显著增高(P<0.05),且HSC3和UM1两种细胞系的EP300内源性表达相对更高。CCK-8增殖实验和克隆形成实验检测发现,沉默EP300后HSC3和UM1的增殖能力明显降低(P<0.05);细胞划痕实验检测发现沉默EP300后HSC3和UM1的迁移能力明显降低(P<0.05)。结论 EP300在口腔鳞癌细胞株HSC3和UM1中高表达,EP300低表达能够抑制口腔鳞癌细胞的增殖和迁移。

关键词: EP300, 口腔鳞状细胞癌, 增殖, 迁移

Abstract:

Objective To investigate the expression level of EP300 in oral squamous carcinoma and its effect on the proliferation and migration of oral squamous carcinoma cells. Methods Differential expression of EP300 gene in pan-cancerous tissues and their normal tissues was collected and analysed through online database. The gene and protein expression levels of EP300 in the normal oral squamous epithelial cell line NOK and two different OSCC cell lines HSC3 and UM1 were detected by RT-PCR and Western blot, respectively; the EP300 gene was silenced in HSC3 and UM1 cell lines by plasmid transfection. Cell proliferation ability was detected by plate cloning and CCK-8, and cell migration ability was detected by scratch assay. Results Bioconductivity analysis revealed that EP300 expression was significantly upregulated in HNSC of head and neck tumors compared to paraneoplastic tissues. EP300 gene and protein expression levels were significantly higher in HSC3 and UM1 compared to the NOK group (P<0.05), and EP300 endogenous expression was relatively higher in both HSC3 and UM1 cell lines. CCK-8 proliferation assay and clone formation assay detected that the proliferation ability of HSC3 and UM1 was significantly reduced after EP300 silencing (P<0.05). Cell scratch assay detected that the migration ability of HSC3 and UM1 was significantly reduced after EP300 silencing (P<0.05). Conclusion EP300 was highly expressed in oral squamous carcinoma cell lines HSC3 and UM1, and low expression of EP300 inhibited the proliferation and migration of oral squamous carcinoma cells.

Key words: EP300, oral squamous cell carcinoma, proliferation, migration

中图分类号:

R780.2

王亚培, 罗玉春, 刘为, 刘畅, 唐婉容. EP300对口腔鳞癌细胞增殖和迁移的影响[J]. 口腔医学, 2024, 44(2): 88-93.

WANG Yapei, LUO Yuchun, LIU Wei, LIU Chang, TANG Wanrong. Effect of EP300 on the proliferation and migration of oral squamous carcinoma cells[J]. Stomatology, 2024, 44(2): 88-93.

图/表 6

表1

图1

图2

图3

图4

图5

参考文献 23

[1]	Liao YH, Chou WY, Chang CW, et al. Chemoprevention of oral cancer:A review and future perspectives[J]. Head Neck, 2023, 45(4):1045-1059. doi: 10.1002/hed.v45.4
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA A Cancer J Clinicians, 2021, 71(1):7-33. doi: 10.3322/caac.v71.1
[3]	Ford PJ, Rich AM. Tobacco use and oral health[J]. Addiction, 2021, 116(12):3531-3540. doi: 10.1111/add.15513 pmid: 33822437
[4]	Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma(OSCC)due to human papillomavirus(HPV)infection and aspects of treatment and prevention[J]. Anticancer Res, 2011, 31(5):1515-1519.
[5]	Agrawal A, Civantos FJ, Brumund KT, et al. [Tc-99m]Tilmanocept accurately detects sentinel lymph nodes and predicts node pathology status in patients with oral squamous cell carcinoma of the head and neck:Results of a phase Ⅲ multi-institutional trial[J]. Ann Surg Oncol, 2015, 22(11):3708-3715. doi: 10.1245/s10434-015-4382-x pmid: 25670018
[6]	Sathiyasekar AC, Chandrasekar P, Pakash A, et al. Overview of immunology of oral squamous cell carcinoma[J]. J Pharm Bioallied Sci, 2016, 8(Suppl 1):S8-S12. doi: 10.4103/0975-7406.191974 pmid: 27829737
[7]	Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases[J]. Cell, 1996, 87(5):953-959. doi: 10.1016/s0092-8674(00)82001-2 pmid: 8945521
[8]	Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development[J]. Genes Dev, 2000, 14(13):1553-1577. doi: 10.1101/gad.14.13.1553
[9]	Kim KB, Kabra A, Kim DW, et al. KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer[J]. Sci Adv, 2022, 8(7):eabl4618. doi: 10.1126/sciadv.abl4618
[10]	Yu YL, Chen M, Zhu H, et al. STAT1 epigenetically regulates LCP2 and TNFAIP2 by recruiting EP300 to contribute to the pathogenesis of inflammatory bowel disease[J]. Clin Epigenetics, 2021, 13(1):127. doi: 10.1186/s13148-021-01101-w
[11]	Van Gils J, Magdinier F, Fergelot P, et al. Rubinstein-taybi syndrome:A model of epigenetic disorder[J]. Genes, 2021, 12(7):968. doi: 10.3390/genes12070968
[12]	Orchard A, Shah F, Prabhu S. Diagnosing OSCC via video[J]. Br Dent J, 2020, 228(12):903-904.
[13]	Madhura MG, Rao RS, Patil S, et al. Advanced diagnostic aids for oral cancer[J]. Dis Mon, 2020, 66(12):101034. doi: 10.1016/j.disamonth.2020.101034
[14]	施雯靖, 潘贤润, 吕哲宇, 等. 口腔鳞状细胞癌遗传变异数据库[J]. 电子科技大学学报, 2022, 51(5):661-667.
[15]	Zhu GM, Pei LJ, Li Y, et al. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients[J]. Aging, 2020, 12(3):2132-2141. doi: 10.18632/aging.v12i3
[16]	Wang LB, Karpova A, Gritsenko MA, et al. Proteogenomic and metabolomic characterization of human glioblastoma[J]. Cancer Cell, 2021, 39(4):509-528. e20. doi: 10.1016/j.ccell.2021.01.006
[17]	Asaduzzaman M, Constantinou S, Min HX, et al. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer[J]. Breast Cancer Res Treat, 2017, 163(3):461-474. doi: 10.1007/s10549-017-4202-z
[18]	Dou CW, Liu ZK, Tu KS, et al. P300 acetyltransferase mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts[J]. Gastroenterology, 2018, 154(8):2209-2221. e14. doi: S0016-5085(18)30209-9 pmid: 29454793
[19]	Henry RA, Kuo YM, Andrews AJ. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4[J]. Biochemistry, 2013, 52(34):5746-5759. doi: 10.1021/bi400684q pmid: 23862699
[20]	Choi JR, Lee SY, Shin KS, et al. p300-mediated acetylation increased the protein stability of HIPK₂ and enhanced its tumor suppressor function[J]. Sci Rep, 2017, 7(1):16136. doi: 10.1038/s41598-017-16489-w
[21]	Waddell AR, Huang HJ, Liao DQ. CBP/p300:Critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers[J]. Cancers, 2021, 13(12):2872. doi: 10.3390/cancers13122872
[22]	Cho YA, Hong JS, Choe EJ, et al. The role of p300 in the tumor progression of oral squamous cell carcinoma[J]. J Oral Pathol Med, 2015, 44(3):185-192. doi: 10.1111/jop.2015.44.issue-3
[23]	Krupar R, Watermann C, Idel C, et al. In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation[J]. Sci Rep, 2020, 10(1):9389. doi: 10.1038/s41598-020-66329-7

基因	正向引物	反向引物
EP300	5'-CCTCGTATGCAACAGCCTTCC-3'	5'-CGGGCAGGAAGAACTAGACAT-3'
GAPDH	5'-GGAGTCCACTGGCGTCTTCA-3'	5'-GTCATGAGTCCTTCCACGATACC-3'